Finished product reference
Iodoquinol
Tablet · Oral · 210 mg
- List code
- 416
- Pharmacologic class
- Luminal amoebicide (hydroxyquinoline)
What it is and how it works
Iodoquinol (diiodohydroxyquinoline) is a halogenated 8-hydroxyquinoline that is poorly absorbed and acts within the intestinal lumen against trophozoites and cysts of Entamoeba histolytica, probably by chelating metal ions essential for the parasite.
Indications
Intestinal amoebiasis, particularly asymptomatic cyst passers, and as luminal follow-up after tissue amoebicides such as metronidazole; also used for Dientamoeba fragilis and Balantidium coli infections.
Dosage and administration (summary)
Adults: 650 mg orally three times daily after meals for 20 days.
Contraindications
Hypersensitivity to iodine or hydroxyquinolines; hepatic or renal impairment; pre-existing optic neuropathy.
Warnings and precautions
Prolonged or high-dose use has been associated with optic neuritis, optic atrophy and peripheral neuropathy; do not exceed the recommended dose or duration. Caution in thyroid disease; the iodine content may interfere with thyroid function tests for several months. Gastrointestinal upset, rash and iodine-related reactions may occur.
Storage and supply
Store below 25 °C, protected from light.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.